Tuesday, 02 January 2024 12:17 GMT

Macrogenics To Participate In The H.C. Wainwright 28Th Annual Global Investment Conference


(MENAFN- GlobeNewsWire - Nasdaq) ROCKVILLE, MD, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 9:30 a.m. ET.

A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at . The Company will maintain an archived replay of the webcasts on its website for 30 days.

About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at . MacroGenics, the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

CONTACT: Contacts: Jim Karrels, Senior Vice President, CFO 1-301-251-5172... Argot Partners 1-212-600-1902...

MENAFN09092026004107003653ID1111643813



GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story